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Introduction
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the 
most common enzymatic red blood cell disorder in humans [1]. 
The G6PD enzyme catalyzes the first step in the pentose phosphate 
pathway, leading to antioxidants that protect cells against oxidative 
damage [2]. A G6PD-deficient patient lacks the ability to protect red blood 
cells against oxidative stresses produced by the taking of certain drugs, 
metabolic conditions, infections, and ingestion of some foods [3,4]. 
This disorder affects about 500 million people but seldom identified 
in populations where malaria is rare but may exceed 10% in prevalence 
where malaria is endemic, since individuals with G6PD deficiency have 
been related to greater levels of resistance to infection by Plasmodium 
falciparum. Therefore, the highest prevalence of G6PD deficiency 
is reported in Africa, Southern Europe, the Middle East, Southeast 
Asia, and the central and southern Pacific islands. However, due to 
migration, deficient alleles are now quite prevalent in North and South 
America and in some Northern European regions [5,6].
G6PD deficiency has been shown to exist due to enzyme variants 
that exhibit less than optimum enzyme activity. These variants reflect 
allelic genes located in the long arm of the X chromosome (Xq28) 
resulting in an X-linked recessive mode of inheritance [7,8]. More than 
160 mutations have been identified as responsible for the deficiency, 
the majority of them consisting of single point mutations causing the 
replacement of amino acids [6]. 
Two of the most common G6PD variants are the Mediterranean 
G6PD B- C563T, mainly encountered in the Mediterranean areas, and 
the African G6PD A- 202A/376G largely found in African subjects [6].
Individuals with G6PD deficiency incur a higher risk of acute 
hemolysis when exposed to some medications such as antimalarials 
or antibiotics, antipyretics and analgesics with healthcare providers 
requiring caution when managing these patients [9]. Special care 
should also be taken in endemic malaria areas since this disease is 
treated with drugs that can cause severe hemolysis in G6PD-deficient 
individuals [10].
Frequently, these patients suffer from cyanosis, headache, fatigue, 
tachycardia, dyspnea, lethargy, lumbar/substernal pain, abdominal 
pain, splenomegaly, hemoglobinuria, and/or scleral icterus. Moreover, 
the broken down products of hemoglobin may accumulate in the 
blood, causing jaundice and excreted in urine, causing a dark brown 
discoloration [3,10-12]. In extreme cases, acute hemolysis can lead to 
permanent neurologic damage or death [8]. 
Strategies to reduce the above mentioned complications associated 
to G6PD deficiency may comprise the screening of newborns/children 
in regions with high frequencies of G6PD deficiency and the capacity 
building of clinical professionals and the awareness of the general 
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population about avoiding those drugs that precipitate attacks of 
hemolytic anemia.
Therefore, our main goal involved determining the frequencies of 
genetic variants of G6PD in children from 0 to 14 years attending the 
Pediatric Hospital in. To the best of our knowledge, this is the first time 
the frequencies of G6PD mutations have been published in Angola.
Methods
A cross-sectional and descriptive analytical study took place 
on 194 children from 0 to 14 years, of both genders, hospitalized at 
the Pediatric Hospital David Bernardino, Luanda, in November and 
December 2011. 
Clinical and biochemical evaluations were performed. Weight, 
hemoglobin values, type of anemia, membrane mucosal coloration, 
diagnosis of malaria and jaundice condition were all taken into 
consideration.
Whole blood samples were collected and stored on 3 mm Cards 
Kit papers. DNA extraction was undertaken by Generation Capture 
Card Kit - DNA Purification; DNA Elution (Gentra Systems, Inc., 
Minneapolis). The G202A, A376G and C563T genotypes were 
determined through Real Time PCR methods with TaqMan Pre-
Designed SNP Genotyping Assays (Applied Biosystems, USA). To 
perform the genotype analysis, the target fragments were amplified in 
20 µl reaction mixture containing 10 µl TaqMan Universal PCR Master 
Mix, 1 µl primers, 5 µl Miliq water and 4 µl DNA. Real Time PCR, 
iCycler iQ® Multicolor Real-Time PCR Detection System (BIO-RAD) 
was conducted as follows: 10 min of the initial step at 95°C, 50 cycles of 
15 sec and 1 min at 92°C and 60°C, respectively with Taqman probes. 
Statistical analysis made recourse to statistical package for the 
social sciences (SPSS) version 21.0 for Windows. Oneway analysis of 
variance (ANOVA) was deployed to test for hemoglobin differences 
between anemia status. The exact test served to compare the mutation 
frequencies and the frequencies of clinical conditions associated to 
different genotypes or gender.
Results
A total of 194 children (92 girls and 102 boys) were analyzed. Ages 
ranged from two days to fourteen years of age but the majority (59%) 
were under two years old, 20% were between two and five, and 21% 
aged over five. Considering the total sample: 33% were underweight; 
anemia was present in 87% of children and 46% of these cases were 
classified as severe; in turn, 85% had microcytic hypochromic anemia. 
The majority of the sample reported neither jaundice nor malaria 
(67%) and had normal mucosal coloration (Table 1).
In Table 2, we set out the frequencies of glucose 6 phosphate 
dehydrogenase genotypes and alleles found in the children of Luanda 
Pediatric Hospital. As expected, B allele was prevalent (60.8%) whereas 
A- was carried by 22.4% of the sample. Moreover, 20.5% of males were 
hemizygous for A- allele and 10.9% of girls were homozygotes for A-. 
Moreover, the Mediterranean mutation (563 C-T) was not detected in 
the sample.
Analyzing the clinical and biochemical characteristics of different 
genotypes for each group, boys or girls, we observed the following: for 
boys, significant differences were found only for jaundice, which was 
absent in B carriers and present in 14% of A-, no other parameters 
were found to significantly differ (Exact test p>0.02); for girls, when 
comparing A- carriers with those without the A- genotype, the first 
group presented a slight increase, although not significant, for anemia, 
severe anemia, microcytic hypochromic anemia, discoloration of 
mucosal membrane and being underweight but with a significant 
increase in the prevalence of jaundice (Exact test p<0.02). Furthermore, 
a slight decrease in malaria diagnoses in girls A- was observed.
No significant differences between hemoglobin concentrations, 
anemia, anemia type (Anova, p>0.05), membrane mucous coloration, 
being underweight or malaria diagnoses were observed between 
boys and girls for the same genotype. On the other hand, significant 
differences between jaundice frequencies were observed, with male 
subjects presenting a higher frequency (Exact test p<0.02) (Table 3). 
*NN normocytic normochromic, NH normocytic hypochromic, MH microcytic 
hypochromic
**Significant differences for boys (Exact test, p= 0.008) and for girls (Exact test, 
p=0.028)
Table 1: Summary of the clinical parameters for the studied population.
Overall
Hemoglobin (g/L)
Mean 7.8
95 CI Mean 7.4-8.1
Median 7.4
Range 2.8-16.9
Anemia [n (%)]
Normal 18 (9%)
Mild 7 (4%)
Moderate 79 (41%)
Severe 90 (46%)
Anemia type [n (%)]*
NN 29 (15%)
NH 27 (14%)
MH 138 (71%)
Membrane mucous coloration [n (%)]
Normal 130 (68%)
Discolored 62 (32%)
Jaundice [n (%)]**
No 183 (94%)
Yes 11 (6%)
Underweight (WAZ) [n (%)]
Normal 121 (67%)
Moderate 23 (13%)
Severe 35 (20%)
Malaria Diagnosis [n (%)]
No 129 (67%)
Yes 65 (33%)
Table 2: Glucose – 6 Phosphate Dehydrogenase genotypes and alleles found in 
the children of Luanda Pediatric Hospital. The Mediterranean mutation (563 C-T) 
was not detected in the sample.
G6PD deficiency n Frequency (%)
Genotypes
Boys 102
B 59 57.8
A 22 21.6
A- 21 20.6
Girls 92
B/B 41 44.6
A/A 2 2.2
A/A- 6 6.5
B/A 16 17.4
B/A- 17 18.5
A-/A- 10 10.9
Alleles 286
B (376A) 174 60.8
A (A376G) 48 16.8
A- (A376G/G202A) 64 22.4
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Discussion
Although there are several G6PD deficiency studies done in 
other African populations, none have been published concerning the 
Angolan population [13]. This preliminary result, carried out in a 
Pediatric Hospital population, addresses the public health problem of 
G6PD deficiencies. However, the epidemiological study of the Angolan 
population is essential to defining a strategy for the implementation of 
population screening. 
The results obtained, in children from 0 to 14 years attending 
the Pediatric Hospital in Luanda, in November and December 2011, 
demonstrated a high frequency of A- variant. A total of 15.9% of 
children were A-, with 10.9% of girls A- homozygotes and 20.5% of 
boys hemyzigotes A-. 
In general, the G6PD A- allele, which contains two mutations, 
A376G and G202A, is the most common G6PD deficiency variant 
in Africa, with a frequency that ranges from 0–25% [13,14]. These 
frequencies are in accordance with those reported by this study. Lower 
frequencies were observed in other African populations namely in the 
4th Nile cataract region in Sudan [15] or in the Republic of Guinea [16]. 
Higher frequencies were detected among Palestinians in the Gaza Strip 
[8] and in Tunisia [6]. Moreover, we searched for the Mediterranean 
allele in the Angolan sample since there are historical references to 
European populations having settled in Angola, in particular the 
Portuguese, where this mutation is prevalent [7]. However, we did not 
encounter the allele in our sample. More studies are needed to confirm 
the presence of this allele in Angola. 
Our data suggest a poor relation between genotypes and the clinical 
G6PD characteristics, except for a significant association with jaundice. 
These results may stem from only making one collection of clinical 
data, in a single moment and not having been able to follow patients 
throughout their hospital stay.
A total of five children with A-genotype were medicated with drugs 
potentially hemolytic, including antibiotics and antimalarials. Since 
this study was retrospective and the children were not followed, there 
are no associations between anemia or jaundice and the medication.
Haemolysis associated with G6PD deficiency has long since been 
described as a serious adverse event for a number of antimalarials 
[17]. However, we did not observe significant differences in Hb values 
among children with a full G6PD defect (hemi- and homozygous), with 
or without treatment with antimalarials. Several possible explanations 
arise, in particular, the fact that we carried out only one determination 
of biochemical parameters, and some children were at the beginning of 
their treatment process while other children were at different phases in 
their treatment courses. That information was not obtained. Another 
explanation is that these children already have very low Hb values 
prior to treatment. In a previous study done in Angola, the prevalence 
of anemia was higher than 40% [18]. Finally, some drugs are only 
capable of provoking crises in patients with the more severely deficient 
polymorphic variants, such as G6PD Mediterranean, but not in the 
mild variant G6PD A- [9]. 
The geographic correlation between malaria endemicity and G6PD 
deficiency suggests that these mutations confer resistance to malaria. 
Clinical data have supported these observations however doubts still 
remain about whether this resistance is just a feature of heterozygous 
females or also hemizygous males [2]. In our results, although not 
significantly, we detected a decrease in malaria infections in females 
A-, but not in males. No differences were observed in heterozygous 
females. Monteiro [19] also did not find evidence for malaria protection 
in carriers of G6PD (A-) allele (hemizygous or heterozygous). A larger 
sample and the follow-up of a cohort of children would be required to 
test the hypothesis of resistance to malaria in the Angolan population.
Our study has some limitations. The sampling time was very short, 
comprising just two months. We were not able to determine G6PD 
activity levels due to technical problems, namely the blood obtained on 
FTA cards that enabled us to extract the enzyme to determine activity. 
*NN normocytic normochromic, NH normocytic hypochromic, MH microcytic hypochromic
**Significant differences for boys (Exact test, p= 0.008) and for girls (Exact test, p=0.028)
Table 3: Summary of the clinical parameters for Angolan children suffering from G6PD hemolytic disorder.
Boys Girls
B and A A- Without A- A/A- and B/A- A-/A-
Hemoglobin (g/L) Mean 7.8 7.3 7.9 7.5 7.8
95 CI Mean 7.3-8.4 6.3-8.3 7.3-8.5 6.5-8.4 5.9-9.5
Median 7.4 7.2 7.4 7.4 6.7
Range 3.4-16.8 2.8-12.8 3.2-16.9 3.5-13.8 5.4-14
Anemia [n (%)] Normal 11 (14%) 2 (10%) 3 (5%) 1 (4%) 1(10%)
Mild 0 (0%) 0 (0%) 5 (9%) 2 (9%) 0 (0%)
Moderate 32 (39%) 8 (38%) 26 (44%) 9 (39%) 4 (40%)
Severe 38 (47%) 11 (52%) 25 (42%) 11 (48%) 5 (50%)
Anemia type [n (%)]* NN 12 (15%) 5 (24%) 9 (15%) 2 (9%) 1 (10%)
NH 12 (15%) 0 (0%) 11 (19%) 3 (13%) 1 (10%)
MH 57 (70%) 16 (76%) 39 (66%) 18 (78%) 8 (80%)
Membrane mucous coloration [n (%)] Normal 56 (70%) 14 (67%) 40 (68%) 15 (65%) 5 (56%)
Discolored 24 (30%) 7 (33%) 19 (32%) 8 (35%) 4 (44%)
Jaundice [n (%)]** No 81 (100%) 18 (86%) 55 (93%) 23 (100%) 6 (60%)
Yes 0 (0%) 3 (14%) 4 (7%) 0 (0%) 4 (40%)
Underweight (WAZ) [n (%)] Normal 49 (65%) 12 (60%) 39 (75%) 16 (72%) 5 (56%)
Moderate 7 (9%) 4 (20%) 5 (10%) 3 (14%) 4 (44%)
Severe 20 (26%) 4 (20%) 8 (15%) 3 (14%) 0 (0%)
Malaria Diagnosis [n (%)] No 52 (64%) 14 (67%) 41 (69%) 14 (61%) 8 (80%)
Yes 29 (36%) 7 (33%) 18 (31%) 9 (39%) 2 (20%)
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Finally, the present study was carried out on a pediatric population 
seeking hospital treatment and the results cannot be generalized to 
the broader Angolan population, however, they do provide important 
preliminary indications of the genotypes frequencies.
Alerting clinical professionals about how frequent the genetic 
variants of G6PD are should contribute to raising awareness about 
the need to screen for G6PD deficiency in children. The potential 
association of G6PD mutations with clinically significant hemolysis 
requiring hospital admission justifies nationwide programs of newborn 
screening for G6PD deficiencies.
Based on the results obtained, it is clearly important to identify 
those with the disabled genotype in the Angolan population in order to 
avoid cases of drug-induced anemia, particularly treating malaria, such 
a frequent condition in Angola.
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